Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Wiegand

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2017
Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ARTAnn Wiegand, Jonathan Spindler, Feiyu F Hong, et al.
The Journal of Infectious Diseases|January 28, 2010
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patientsElias K Halvas, Ann Wiegand, Valerie F Boltz, et al.
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
The Journal of Infectious Diseases|August 7, 2009
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parametersFlorencia Pereyra, Sarah Palmer, Toshiyuki Miura, et al.
Plos One|February 25, 2012
Multiple sources of contamination in samples from patients reported to have XMRV infectionMary F Kearney, Jonathan Spindler, Ann Wiegand, et al.
Plos Pathogens|March 23, 2017
Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoirJohn K Bui, Michele D Sobolewski, Brandon F Keele, et al.
AIDS (London, England)|June 6, 2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cellsNancy M Archin, Joseph J Eron, Sarah Palmer, et al.
Lancet (London, England)|August 16, 2005
Depletion of latent HIV-1 infection in vivo: a proof-of-concept studyGinger Lehrman, Ian B Hogue, Sarah Palmer, et al.
Plos Pathogens|October 15, 2019
Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individualsElizabeth R Wonderlich, Krupa Subramanian, Bryan Cox, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2012
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infectionNancie M Archin, Naveen K Vaidya, Joann D Kuruc, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2017
Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ARTAnn Wiegand, Jonathan Spindler, Feiyu F Hong, et al.
The Journal of Infectious Diseases|January 28, 2010
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patientsElias K Halvas, Ann Wiegand, Valerie F Boltz, et al.
Plos One|May 8, 2014
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)John E McKinnon, Robbie B Mailliard, Susan Swindells, et al.
The Journal of Infectious Diseases|August 7, 2009
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parametersFlorencia Pereyra, Sarah Palmer, Toshiyuki Miura, et al.
Plos One|February 25, 2012
Multiple sources of contamination in samples from patients reported to have XMRV infectionMary F Kearney, Jonathan Spindler, Ann Wiegand, et al.
Plos Pathogens|March 23, 2017
Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoirJohn K Bui, Michele D Sobolewski, Brandon F Keele, et al.
AIDS (London, England)|June 6, 2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cellsNancy M Archin, Joseph J Eron, Sarah Palmer, et al.
Lancet (London, England)|August 16, 2005
Depletion of latent HIV-1 infection in vivo: a proof-of-concept studyGinger Lehrman, Ian B Hogue, Sarah Palmer, et al.
Plos Pathogens|October 15, 2019
Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individualsElizabeth R Wonderlich, Krupa Subramanian, Bryan Cox, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2012
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infectionNancie M Archin, Naveen K Vaidya, Joann D Kuruc, et al.
Pageof 4